|
| 37303270 | An Introductory Tutorial on Cardiovascular Pharmacogenetics for Healthcare Providers. | Clin Pharmacol Ther | 2023 |
| 37961335 | <i>CYP2C19</i> Polymorphisms and Clinical Outcomes Following Percutaneous Coronary Intervention (PCI) in the Million Veterans Program. | medRxiv | 2023 |
| 35652783 | Cost-effectiveness of CYP2C19-guided P2Y12 inhibitors in Veterans undergoing percutaneous coronary intervention for acute coronary syndromes. | Eur Heart J Qual Care Clin Outcomes | 2023 |
| 35576481 | An antiplatelet response gene expression signature is associated with bleeding. | Cardiovasc Res | 2023 |
| 37218594 | Branched-Chain Amino Acids in Computed Tomography-Defined Adipose Depots and Coronary Artery Disease: A PROMISE Trial Biomarker Substudy. | J Am Heart Assoc | 2023 |
| 37210707 | Veterans Health Administration: Implementation of pharmacogenomic clinical decision support with statin medications and the SLCO1B1 gene as an exemplar. | Am J Health Syst Pharm | 2023 |
| 34705291 | Aspirin effects on platelet gene expression are associated with a paradoxical, increase in platelet function. | Br J Clin Pharmacol | 2022 |
| 35616642 | Gene Expression Profiles of Treatment Response and Non-Response in Children With Juvenile Dermatomyositis. | ACR Open Rheumatol | 2022 |
| 35768902 | Platelet inhibition by low-dose aspirin is not influenced by body mass or weight. | Platelets | 2022 |
| 35468922 | Risk factors, transcriptomics, and outcomes of myocardial injury following lower extremity revascularization. | Sci Rep | 2022 |
| 35605652 | Associations of a polygenic risk score with coronary artery disease phenotypes in the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. | Am Heart J | 2022 |
| 35466688 | A precision medicine approach to stress testing using metabolomics and microribonucleic acids. | Per Med | 2022 |
| 35365302 | Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. | Value Health | 2022 |
| 35819423 | Effect of Pharmacogenomic Testing for Drug-Gene Interactions on Medication Selection and Remission of Symptoms in Major Depressive Disorder: The PRIME Care Randomized Clinical Trial. | JAMA | 2022 |
| 35926901 | Coronary Atherosclerosis, Cardiac Troponin, and Interleukin-6 in Patients With Chest Pain: The PROMISE Trial Results. | JACC Cardiovasc Imaging | 2022 |
| 36281983 | Risk factors for cardiovascular disease among individuals with hepatic steatosis. | Hepatol Commun | 2022 |
| 35319502 | Drug-drug-gene interaction risk among opioid users in the U.S. Department of Veterans Affairs. | Pain | 2022 |
| 35152405 | The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. | Clin Pharmacol Ther | 2022 |
| 35034348 | SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care. | Clin Pharmacol Ther | 2022 |
| 32707340 | Association of Hepatic Steatosis With Major Adverse Cardiovascular Events, Independent of Coronary Artery Disease. | Clin Gastroenterol Hepatol | 2021 |
| 34704830 | Evaluation of the Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program at initial test sites. | Pharmacogenomics | 2021 |
| 34787561 | United States Emergency Department Use of Medications with Pharmacogenetic Recommendations. | West J Emerg Med | 2021 |
| 34516880 | Platelets amplify endotheliopathy in COVID-19. | Sci Adv | 2021 |
| 34276225 | Delivery of Pharmacogenetic Testing with or without Medication Therapy Management in a Community Pharmacy Setting. | Pharmgenomics Pers Med | 2021 |
| 34290521 | Independent Community Pharmacists' Experience in Offering Pharmacogenetic Testing. | Pharmgenomics Pers Med | 2021 |
| 33403869 | Veterans Affairs Pharmacogenomic Testing for Veterans (PHASER) clinical program. | Pharmacogenomics | 2021 |
| 33159252 | Platelet reactivity in response to aspirin and ticagrelor in African-Americans and European-Americans. | J Thromb Thrombolysis | 2021 |
| 33448876 | North Carolina's multi-institutional pharmacogenomics efforts with the North Carolina Precision Health Collaborative. | Pharmacogenomics | 2021 |
| 32308127 | Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. | Pharmacogenomics | 2020 |
| 31952675 | Cost-Effectiveness of Multigene Pharmacogenetic Testing in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention. | Value Health | 2020 |
| 31852401 | Longitudinal RNA-Seq Analysis of the Repeatability of Gene Expression and Splicing in Human Platelets Identifies a Platelet <i>SELP</i> Splice QTL. | Circ Res | 2020 |
| 33237943 | Modeling statin myopathy in a human skeletal muscle microphysiological system. | PLoS One | 2020 |
| 32980074 | Identifying End Users' Preferences about Structuring Pharmacogenetic Test Orders in an Electronic Health Record System. | J Mol Diagn | 2020 |
| 31049556 | Genetic influences on aspirin response in patients undergoing percutaneous coronary intervention. | Cardiovasc Res | 2019 |
| 31684818 | Effect of aspirin response signature gene expression on preterm birth and preeclampsia among women with lupus: a pilot study. | Lupus | 2019 |
| 29851527 | Equilibrative nucleoside transporter 1 gene polymorphisms and clinical outcomes following acute coronary syndromes: findings from the PLATelet inhibition and patient Outcomes (PLATO) study. | Platelets | 2019 |
| 30707740 | Pilot study of myocardial ischemia-induced metabolomic changes in emergency department patients undergoing stress testing. | PLoS One | 2019 |
| 29102571 | Multisite Investigation of Outcomes With Implementation of CYP2C19 Genotype-Guided Antiplatelet Therapy After Percutaneous Coronary Intervention. | JACC Cardiovasc Interv | 2018 |
| 30354330 | Effects of Delivering SLCO1B1 Pharmacogenetic Information in Randomized Trial and Observational Settings. | Circ Genom Precis Med | 2018 |
| 29569527 | Future directions in pharmacogenomics discovery in cardiovascular disease. | Pharmacogenomics | 2018 |
| 29329538 | Peripheral blood gene expression signatures which reflect smoking and aspirin exposure are associated with cardiovascular events. | BMC Med Genomics | 2018 |
| 27864383 | Use of Pharmacogenetic Information in the Treatment of Cardiovascular Disease. | Clin Chem | 2017 |
| 28224927 | An age- and sex-specific gene expression score is associated with revascularization and coronary artery disease: Insights from the Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial. | Am Heart J | 2017 |
| 28244804 | Assessing feasibility of delivering pharmacogenetic testing in a community pharmacy setting. | Pharmacogenomics | 2017 |
| 28294551 | The IGNITE Pharmacogenetics Working Group: An Opportunity for Building Evidence with Pharmacogenetic Implementation in a Real-World Setting. | Clin Transl Sci | 2017 |
| 29155848 | An electronic health record based model predicts statin adherence, LDL cholesterol, and cardiovascular disease in the United States Military Health System. | PLoS One | 2017 |
| 28676520 | Transcription Factor RUNX1 Regulates Platelet <i>PCTP</i> (Phosphatidylcholine Transfer Protein): Implications for Cardiovascular Events: Differential Effects of RUNX1 Variants. | Circulation | 2017 |
| 28832186 | The need for sex-specific precision biomarkers for antiplatelet therapies. | Future Cardiol | 2017 |
| 28760750 | The Expressed Genome in Cardiovascular Diseases and Stroke: Refinement, Diagnosis, and Prediction: A Scientific Statement From the American Heart Association. | Circ Cardiovasc Genet | 2017 |
| 26965543 | Pharmacometabolomics Meets Genetics: A "Natural" Clinical Trial of Statin Effects. | J Am Coll Cardiol | 2016 |